Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Aegerion, Isis, Sanofi Make Case for Drugs to Treat Severe Cholesterol


Isis is dropping and Aegerion is rallying ahead of government panels that will consider a pair of drugs aimed at treating familial hypercholesterolemia. The rare condition raises cholesterol and causes heart attacks among the young.

MINYANVILLE ORIGINAL A rare genetic condition that causes heart attacks at a young age is getting a lot of attention this week as rival companies tout a pair of experimental drugs aimed at treating the disease.

Aegerion Pharmaceuticals (NASDAQ:AEGR) will appear before a panel of government advisers Wednesday to discuss its oral treatment lomitapide for homozygous familial hypercholesterolemia, a condition characterized by very high levels of bad cholesterol. The drug has a risk of liver damage, but comments made by Food and Drug Administration staff in a report prior to Wednesday's meeting cheered investors who have bid up the stock 15% in two days. A positive recommendation by the advisers may bode well for possible FDA approval, which explains the rise in the stock.

Isis Pharmaceuticals (NASDAQ:ISIS) and partner Sanofi (NYSE:SNY) are also developing a treatment for the genetic condition, the injected drug mipomersen sodium. But some investors aren't so confident that this drug, branded Kynamro, is on the path to approval. Shares of Isis fell 19% Tuesday after another FDA staff report noting safety concerns of Kynamro, including risk of possible tumor growth. Isis and Sanofi's Genzyme face an FDA panel on Thursday.

Isis traded at $10.69 midday Tuesday. The shares are still up 48% this year. Aegerion's stock was $18.25 midday. Those shares are up more than 40% over the past six months. The US shares of Paris-based Sanofi rose 3% to $45.13 Tuesday.

The reports prepared for the panels are used to guide discussion among the advisers. The panelists will vote on the merits of both drugs, sending their recommendations to the FDA, which considers the advice as part of the approval process. The FDA isn't bound by any recommendation made. In fact, the agency sometimes goes against the advice of a panel. But if the experts are overly concerned about safety issues of particular drugs, there's a good chance the FDA will not approve a drug.

The FDA is expected to rule on Aegerion's drug by the end of the year and on the Isis-Sanofi treatment in January. Currently, the most common treatment for patients with homozygous familial hypercholesterolemia are cholesterol-lowering statins such as Pfizer's (NYSE:PFE) Lipitor.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos